Select the drug indication to add to your list

Bacterial infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:


Generic Name and Formulations:
Tobramycin 300mg/5mL; amps; soln for inhalation; preservative-free.

Novartis Pharmaceuticals Corp

Therapeutic Use:

Indications for TOBI:

Management of cystic fibrosis patients with P. aeruginosa.

Adults and Children:

<6yrs: not studied. Use the correct nebulizer/compressor. Administer by inhalation over a 15-minute period. Give in alternate 28-day cycles (28 days on, 28 days off). ≥6yrs: 300mg (1 amp) twice daily, as close to every 12hrs as possible (must be at least 6hrs apart). Give last when using multiple inhalation therapies.


Safety and efficacy have not been demonstrated in patients <6yrs, in those with FEV1 <25% or >75% predicted, or patients colonized with B. cepacia. Known or suspected auditory, vestibular, renal, or neuromuscular dysfunction. Myasthenia gravis. Parkinson's disease. Consider performing an audiogram at baseline (esp. at risk of auditory dysfunction). Monitor for high frequency hearing loss if tinnitus occurs. Monitor serum tobramycin levels in renal dysfunction patients or if treated with concomitant IV tobramycin. Discontinue if nephrotoxicity occurs; may restart when serum tobramycin <2µg/mL. Monitor renal function as needed. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Pharmacological Class:



Concomitant ethacrynic acid, furosemide, urea, IV mannitol: not recommended. Diuretics may increase toxicity. Avoid concurrent or sequential use of other oto-, neuro-, or nephrotoxic drugs. Do not mix in nebulizer with dornase alfa.

Adverse Reactions:

Voice alteration, tinnitus (follow-up if occurs), bronchospasm.

How Supplied:

Single-use amps (5mL)—56

Sign Up for Free e-newsletters

CME Focus